Cliintel Capital

Cliintel Capital is a pioneering venture capital firm at the forefront of capital structuring in the cannabis industry. Founded in 2015, the firm has established itself as the 1st Qualified Institutional Investment capital firm with the Marijuana Enforcement Division of Colorado, enabling outside investors to own equity in licensed cannabis businesses while remaining passive unlicensed investors. The firm has strategically invested in various crucial functions of the cannabis industry, thereby creating a conglomerate of symbiotic cannabis companies licensed legally through the fund with the Marijuana Enforcement Division and the SEC. This unique structure offers investors a globally unparalleled opportunity to invest in a diversified professionally-managed venture capital fund without direct licensing exposure to the cannabis industry, thereby mitigating risk. Cliintel Capital aims to instill confidence in this burgeoning industry by providing regulated, licensed, and professionally managed funds appealing to accredited investors, family offices, and private equity funds seeking exposure to the cannabis sector at return rates justifying the risk. Notably, the firm boasts a track record, institutional equity holdings in licensed entities, and most importantly, ensures quality professional management of venture capital in cannabis. With its focus on creating value through the alignment of people, ideas, and resources, Cliintel Capital stands as a prominent player in the cannabis venture capital landscape, offering an opportunity for investors to participate in the industry's growth with confidence.